Novartis and Gilead’s CAR-T therapies have been approved in Europe – and the UK’s NICE immediately slapped down the latter, saying it is too expensive for regular NHS use in England and Wales.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback